In the vast field of modern medicine, there is a little-known group of 'heroes' silently saving and improving countless lives. They are medical isotopes. When loved ones face major challenges such as cancer or heart disease, these tiny yet powerful particles are often the key to diagnosis and treatment. Although the term 'radioactive' may sound unsettling, medical isotopes are precisely controlled and effectively utilized in medical applications, bringing enormous benefits to human health.
Medical isotopes are the cornerstone of nuclear medicine diagnosis and treatment, and their unique radioactivity gives them irreplaceable advantages in early diagnosis and precise treatment of diseases. They can not only provide detailed information on human functions and metabolism for early diagnosis before morphological and structural changes occur in lesions, but also use their radiation to accurately kill diseased tissues, achieve the clearance of small lesions, and achieve significant therapeutic effects. Ensuring stable supply of these critical medical resources has become a common priority for the global healthcare system.

1. What is medical isotope? The 'invisible guardian' of life and health
Medical isotopes are atoms of the same element with the same number of protons but different numbers of neutrons in the periodic table. Those that can emit radiation on their own are called "radioactive isotopes", and the radioactive isotopes used in the medical field are medical isotopes. Although they are 'invisible', they play an indispensable role in the field of life and health.
Application of Nuclear Medicine - Diagnosis and Early Detection
In terms of diagnosis, medical isotopes can provide key information about human function and metabolism, which enables doctors to diagnose diseases in the early stages, even before the lesions cause structural changes. For example, they are widely used in the diagnosis of cardiovascular and cerebrovascular diseases, neurodegenerative diseases, and various malignant tumors.
Nuclear medicine diagnosis mainly relies on specific imaging techniques, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). These technologies utilize the aggregation and radioactive decay of medical isotopes such as technetium-99m and fluorine-18 in specific parts of the body to generate images of organ function and metabolism, thereby helping doctors detect abnormalities. This ability is crucial for early detection and intervention, as many diseases have much better treatment outcomes in the early stages than in the late stages. The role of medical isotopes in healthcare is so fundamental and profound that they have become an indispensable component of modern precision medicine systems. Although the public may not know much about their specific mechanisms, their contribution to life and health is evident.
Application of Nuclear Medicine - Precision Therapy
The application of medical isotopes in treatment is also revolutionary. They can be made into drugs, and once injected into the patient's body, these drugs selectively accumulate in the diseased tissue (especially tumors), using their radiation to precisely kill cancer cells while minimizing damage to surrounding healthy tissues. This method, known as "precision oncology" or "radiation therapy," is changing the treatment landscape of various cancers.
For example, Lutetium-177 (Lu-177) is used to treat neuroendocrine tumors and prostate cancer. Ho-166 plays a role in the treatment of liver cancer by directly delivering radiation to the tumor site. In addition, actinium-225 (Ac-225) is an extremely rare radioactive isotope, with a global annual production of less than a grain of sand. However, it has shown great potential in targeted alpha therapy and is considered a new weapon in the fight against cancer. A significant trend in the current field of nuclear medicine is that although diagnostic isotopes still dominate the market share, the market for therapeutic isotopes is expected to grow rapidly at a significant compound annual growth rate. This indicates that nuclear medicine is evolving from a simple diagnostic tool to more targeted and personalized treatment plans, thereby bringing more optimized treatment outcomes to patients.
Other important uses
In addition to diagnosis and treatment, medical isotopes have other important applications. For example, cobalt-60 (Co-60) is widely used for sterilization of medical equipment to ensure the sterility and safety of medical supplies.
The following table summarizes the main uses of medical isotopes and their representative isotopes:


2. Global Medical Isotope Supply Chain: Challenges and Opportunities Coexist
The production and supply of medical isotopes is a complex global system that has long faced many challenges, but is also ushering in unprecedented development opportunities.
Historical fragility and complexity
For decades, the production of key medical isotopes (such as molybdenum-99, Mo-99, which is the parent of the most widely used diagnostic isotope technetium-99m) has been highly dependent on a few aging research reactors worldwide. These facilities often encounter unexpected interruptions and shutdowns due to aging infrastructure. For example, between 2009 and 2010, there was a severe shortage of molybdenum-99 worldwide, resulting in a large number of medical procedures being cancelled or diagnoses being delayed. The National Research Union (NRU) reactor in Canada ceased production of molybdenum-99 in 2016 and permanently shut down in 2018, further highlighting the fragility of the supply system.
The inherent short half-life characteristic of medical isotopes means that they must be transported and used quickly after production, making the entire supply chain extremely complex and susceptible to interference. For example, technetium-99m needs to be transported to the hospital within a few hours after production and has a 94% radioactive decay within 24 hours. This time sensitivity requires a highly coordinated and seamless connection between production and logistics chains.
Although the supply of key medical isotopes has stabilized since 2017, experts such as the International Atomic Energy Agency (IAEA) have pointed out that potential vulnerabilities still exist. The hidden risks in this seemingly stable situation are the fundamental reason why countries and regions need to continue investing and strategic planning to ensure long-term resilience.
Global Market Overview and Growth Forecast
Despite facing challenges, the global medical isotope production market is showing a strong growth trend. The market is valued at approximately $4.35 billion in 2024, expected to reach $4.71 billion by 2025, and is expected to increase to approximately $9.69 billion by 2034, with a compound annual growth rate (CAGR) of 8.34% from 2025 to 2034.
This growth is mainly driven by the increasing demand for nuclear medicine in cancer and heart disease diagnosis worldwide; Supportive policies of governments towards domestic isotope production; And continuous improvement of production methods based on cyclotrons and reactors. From a regional perspective, the North American market will dominate in 2024, with a market share of up to 58%. However, the Asia Pacific region is expected to become the fastest-growing region, thanks to the increase in medical expenditures, the growing popularity of nuclear imaging procedures, and the government's active promotion of domestic isotope production.

3. Double the production of medical isotopes by 2030
Canada has a 75 year history in nuclear medicine and pioneered the medical isotope industry as early as the 1950s. Among them, Ontario's contribution is particularly outstanding. Currently, Ontario's nuclear reactors produce approximately 50% of the isotopes used globally for the treatment of head and neck cancer and cervical cancer, as well as isotopes used for sterilization of medical equipment.
The main production bases for medical isotopes in Ontario include three nuclear power plants within the province (Bruce, Pickering, and Darlington) and the McMaster University nuclear reactor. In addition, Chalk River Laboratories has long been at the forefront of health research and medical isotope development.
Diversification and cutting-edge isotope production
Ontario's nuclear facilities are capable of producing a variety of critical medical isotopes, covering a wide range of applications such as diagnosis, treatment, and sterilization
Molybdenum 99 (Mo-99): Historically, Jocke River Laboratory was a major producer of molybdenum-99 worldwide, accounting for 30% to 80% of global demand at one point. Although the NRU reactor has ceased production, Ontario Power Company (OPG) plans to produce molybdenum-99 at the Darlington nuclear power plant to ensure a continuous supply of this critical diagnostic isotope.
Lutetium-177 (Lu-177): Bruce Power Company is the world's first commercial nuclear reactor to produce Lutetium-177, an isotope crucial for precise treatment of prostate cancer and neuroendocrine tumors.
Iodine-125 (I-125): McMaster University's nuclear reactor is a major supplier of iodine-125 globally, accounting for half of the total global production. It benefits over 70000 cancer patients worldwide annually and is used for the treatment of prostate cancer and other conditions.
Ho-166: McMaster University is also a major global supplier of Ho-166, which plays a critical role in liver cancer treatment by delivering radiation directly to the tumor site.
Cobalt-60 (Co-60): Canadian nuclear power plants (including Bruce and Pickering) produce over 70% of the world's cobalt-60, an isotope used to sterilize over 40% of disposable medical equipment worldwide.
Actinium-225 (Ac-225): The Jock River Laboratory is one of the few institutions in the world capable of producing actinium-225 on a research scale. This extremely rare radioactive isotope has shown great potential in targeted alpha therapy and is seen as a hope for the next generation of cancer treatments.
Ontario's contribution in the field of medical isotopes is not only reflected in production, but also in the breadth of its production range. Ontario's production capacity covers the entire spectrum of medical isotope applications, from high-yield diagnostic isotopes to cutting-edge therapeutic isotopes for specific cancers, and to critical isotopes required for sterilization of medical equipment. This strategic diversification of production greatly enhances its relevance and resilience in the global market.
In response to the growing global demand for precision cancer treatment and to further consolidate its leadership position in the global nuclear medicine field, the Ontario government has announced an ambitious plan to double the province's medical isotope production by 2030. The core driving force behind this goal is to bring hope to cancer patients and ensure that they have fair access to life-saving treatment.
Strategic initiatives and investments
To achieve this goal, Ontario is taking a series of strategic initiatives and significant investments:
Establishment of the Nuclear Isotope Innovation Council (NIICO): Ontario has formed a new expert advisory group, the Nuclear Isotope Innovation Council (NIICO), consisting of top experts from the medical, nuclear, and research fields. The committee's task is to guide this expansion plan and identify new opportunities to meet the growing demand for precision cancer therapies, while strengthening the supply chain and consolidating Ontario's global competitiveness. It is expected that the committee will submit preliminary investigation results before September 2025.
Infrastructure upgrade and expansion:
Bruce Power Company: The company is installing a second isotope production line to double the production capacity of lutetium 177, expected to be completed by the end of 2024. In addition, a new "hot chamber" is being constructed in Bruce County to bring the processing flow of lutetium 177 back into the province, thereby reducing overall processing time and improving efficiency.
McMaster University: In March 2023, the Ontario government invested $6.8 million in the expansion of McMaster University's nuclear reactor, allowing it to operate 24 hours a day, five days a week, significantly increasing isotope production.
Reactor refurbishment: Darlington, Bruce (Units 3 to 8 are planned to be completed by 2033), and potential Pickering nuclear power plants are undergoing large-scale renovations, which will extend their operational lifespan by at least 30 years and ensure long-term reliable production capacity.
Small Modular Reactors (SMRs): The world's first small modular reactor under construction in Darlington will further enhance Ontario's market share in the rapidly expanding isotope market.